PATENT CLAIM ANALYSIS

Application Number: 16211564
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "218100"]

Abstract:
The invention provides a recombinant polypeptide comprising the EDIII domain of each of Dengue virus serotype DENV-1, DENV-2, DENV-3, and DENV-4 linked to the N-terminal of HBsAg.

Claim (Index 13):
The tetravalent dengue virus vaccine of claim  1  for use in eliciting neutralizing antibody titer against each of the four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 1.19231
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15506379', '15320033', '15523899', '14130839', '14921701']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7905517660439474
- 35 USC 102 Novelty (BERT): 0.6560285372025951
- Combined Prediction Score: 0.7770994431598122
- Mean Citation Score: 440.981272
- Max Citation Score: 758.35583
- Similarity Product: 586.752380425372

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test